Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis

BACKGROUND: Lanreotide and octreotide acetate suspension for injectable (LAR) are both recommended for clinical use in patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors. However, each agent possesses unique attributes in terms of their drug-delivery characteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, P, McBride, A, Ray, D, Pulgar, S, Ramirez, RA, Elquza, E, Favaro, JP, Dranitsaris, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643159/
https://www.ncbi.nlm.nih.gov/pubmed/30924737
http://dx.doi.org/10.1177/1078155219839458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643159/
https://www.ncbi.nlm.nih.gov/pubmed/30924737
http://dx.doi.org/10.1177/1078155219839458

Ejemplares similares